| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/05/2002 | US20020182185 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| 12/05/2002 | US20020182183 With a bioactive ingredient such as vitamin, nutrient or mineral; increases stability and bioactivity of the active ingredient |
| 12/05/2002 | US20020182177 Methods and compositions for promoting the maturation of monocytes |
| 12/05/2002 | US20020182176 Methods and compositions for promoting the maturation of monocytes |
| 12/05/2002 | US20020182175 Administration of a reactive oxygen species (ROS) inhibitor or scavenger (a histmine or its salt, ester, prodrug and agonist) and at least one monocyte maturation promoting agent (a cytokine) |
| 12/05/2002 | US20020182174 Methods and compositions for promoting the maturation of monocytes |
| 12/05/2002 | US20020182172 A water soluble and non-peptidic polymer backbone covalently attached to a non-heteroatom position of a triazine derivative comprising a triazine ring |
| 12/05/2002 | US20020182171 Sulphonated comb polymers and preparations, in particular hair cosmetic preparations, based on such sulphonated comb polymers |
| 12/05/2002 | US20020182168 Administering to a patient a therapeutically effective amount of an amine polymer, wherein the amine polymer is water insoluble or nonabsorbent in the gastrointestinal tract to treat the copper toxicosis and Wilson's disease |
| 12/05/2002 | US20020182162 Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth |
| 12/05/2002 | US20020182156 Contacting the melanocyte with a melanin synthesis inhibiting amount of a fatty acid synthase (FAS) inhibitor (such as cerulenin) to reduce melanin synthesis in the melanocyte |
| 12/05/2002 | US20020182155 Multifunctional particulate additive for personal care and cosmetic compositions, and the process of making the same |
| 12/05/2002 | US20020182147 Vitronectin receptor antagonist pharmaceuticals |
| 12/05/2002 | US20020179087 Pharmaceutical compositions containing an oxitropium salt and a betamimetic |
| 12/05/2002 | DE10126924A1 Inhalation capsule contains powdered mixture of tiotropium and auxiliary, for treating asthma or chronic obstructive pulmonary disease, having capsule material of low moisture content to improve stability |
| 12/05/2002 | DE10126434A1 New tricyclic thiochromenone derivatives as metabotropic glutamate receptor-1 (mGluR1) antagonists useful for treating e.g. hemorrhagic stroke and atherosclerosis, especially pain or neurodegenerative diseases |
| 12/05/2002 | DE10126396A1 Cosmetic or dermatological preparations containing glucosamine, useful e.g. for treatment, care and prophylaxis of sensitive skin and treatment of inflammatory conditions such as eczema or psoriasis |
| 12/05/2002 | DE10126163A1 Solid, semi-solid or liquid pharmaceutical or cosmetic preparations, containing pyrogenic silicon dioxide of high tamped density as auxiliary to provide good flow properties |
| 12/05/2002 | DE10125179A1 Verwendung von LPS zur Behandlung intestinaler Entzündungsprozesse Use of LPS to treat intestinal inflammation |
| 12/05/2002 | DE10124820A1 Zusammensetzung und Verwendung von Substanzen zur Stabilisierung von schwefelhaltigen Aminosäuren im Blut Composition and use of substances for the stabilization of sulfur-containing amino acids in blood |
| 12/05/2002 | DE10118282A1 Haftkleber auf Basis von Ethylen-Vinylacetat-Copolymeren und Klebharzen, für medizinische Verwendungszwecke Pressure-sensitive adhesives based on ethylene-vinyl acetate copolymers and tackifier resins, for medical uses |
| 12/05/2002 | CA2487014A1 A method of improving the growth performance of an animal |
| 12/05/2002 | CA2459176A1 Oral composition comprising an extract from the bark of albizzia myriophylla |
| 12/05/2002 | CA2455341A1 Novel ligand for nicotinic acetylcholine receptors useful in therapy |
| 12/05/2002 | CA2452154A1 Carbohydrate modifying agent and drinks containing the modifying agent |
| 12/05/2002 | CA2451845A1 Ptpase inhibitors and method of using same |
| 12/05/2002 | CA2449245A1 Small molecule antagonists of bcl2 family proteins |
| 12/05/2002 | CA2449199A1 Coenzyme q and eicosapentaenoic acid (epa) |
| 12/05/2002 | CA2449173A1 An arylation method for the functionalization of o-allyl erythromycin derivatives |
| 12/05/2002 | CA2449160A1 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| 12/05/2002 | CA2449118A1 Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| 12/05/2002 | CA2449019A1 Method for treating nerve injury caused by surgery |
| 12/05/2002 | CA2449017A1 Neuroblastoma cell lines expressing the alpha2delta subunit of calcium channels and methods therefore |
| 12/05/2002 | CA2449009A1 Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
| 12/05/2002 | CA2449006A1 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| 12/05/2002 | CA2448963A1 Pharmaceutical use for secreted bacterial effector proteins |
| 12/05/2002 | CA2448956A1 Anti-ngf antibodies for the treatment of various disorders |
| 12/05/2002 | CA2448894A1 Cinnamide derivatives as kcnq potassium channel modulators |
| 12/05/2002 | CA2448645A1 New phenylalkyloxy-phenyl derivatives |
| 12/05/2002 | CA2448643A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a biguanide drug |
| 12/05/2002 | CA2448637A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin |
| 12/05/2002 | CA2448627A1 Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol |
| 12/05/2002 | CA2448626A1 Carbamate and oxamide compounds as inhibitors of cytokine production |
| 12/05/2002 | CA2448567A1 Modulators of nucleic acid ligands |
| 12/05/2002 | CA2448562A1 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy |
| 12/05/2002 | CA2448528A1 Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment |
| 12/05/2002 | CA2448438A1 Soft elastic capsules comprising ritonavir and/or lopinavir |
| 12/05/2002 | CA2448363A1 Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways |
| 12/05/2002 | CA2448320A1 Ribozyme based treatment of female reproductive diseases |
| 12/05/2002 | CA2448317A1 Method for treating glaucoma v |
| 12/05/2002 | CA2448306A1 Method for treating fibrotic diseases or other indications |
| 12/05/2002 | CA2448305A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| 12/05/2002 | CA2448294A1 Method for treating fibrotic diseases or other indications vi |
| 12/05/2002 | CA2448276A1 Method for treating glaucoma vi |
| 12/05/2002 | CA2448248A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases |
| 12/05/2002 | CA2448246A1 Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia |
| 12/05/2002 | CA2448241A1 Conjugated nonadecadienoic acid compositions |
| 12/05/2002 | CA2448205A1 Oxazol/thiazol-derivatives activators of the hppar-alpha receptor |
| 12/05/2002 | CA2448198A1 5-substituted-2-arylpyridines as crf1 modulators |
| 12/05/2002 | CA2448192A1 Pyrimidine derivatives useful as selective cox-2 inhibitors |
| 12/05/2002 | CA2448160A1 Heterocyclic beta-amino acids and their use as anti-epileptogenic agents |
| 12/05/2002 | CA2448104A1 Wnv core protein/capsid interacting protein and uses of the same |
| 12/05/2002 | CA2448103A1 Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases |
| 12/05/2002 | CA2448101A1 Process for preparing a thialzole ppar-ligand and polymorphs thereof |
| 12/05/2002 | CA2448086A1 An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases |
| 12/05/2002 | CA2448081A1 Medicinal compositions |
| 12/05/2002 | CA2448068A1 Drug preparations |
| 12/05/2002 | CA2448062A1 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 12/05/2002 | CA2448023A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments |
| 12/05/2002 | CA2447884A1 Use of azetidinone substituted derivatives in the treatment of alzheimer's disease |
| 12/05/2002 | CA2447879A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 12/05/2002 | CA2447693A1 Taste-masking of highly water-soluble drugs |
| 12/05/2002 | CA2447657A1 Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease |
| 12/05/2002 | CA2447648A1 Pharmaceutical combinations |
| 12/05/2002 | CA2447562A1 Pirenzepine ophthalmic gel |
| 12/05/2002 | CA2447475A1 Hydantion derivatives as inhibitors of matrix metalloproteinases |
| 12/05/2002 | CA2446723A1 Antibodies that immunospecifically bind to trail receptors |
| 12/05/2002 | CA2446613A1 A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases |
| 12/05/2002 | CA2446532A1 Aryl-8-azabicyclo[3.2.1]octanes for the treatment of depression |
| 12/05/2002 | CA2445712A1 Store operated calcium influx inhibitors and methods of use |
| 12/05/2002 | CA2445650A1 Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways |
| 12/05/2002 | CA2445611A1 P-cadherin as a target for anti-cancer therapy |
| 12/05/2002 | CA2443350A1 Ultrashort-acting opioids for transdermal application |
| 12/05/2002 | CA2443346A1 Anticholinergic compounds and methods of use |
| 12/05/2002 | CA2441937A1 Chromosome-based platforms |
| 12/05/2002 | CA2411907A1 Preparation with vascular protective and anti-oxidative effect and use thereof |
| 12/05/2002 | CA2411549A1 Ligands of integrin receptors |
| 12/05/2002 | CA2411082A1 Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament |
| 12/04/2002 | EP1262541A1 Production of bioavailable folic acid |
| 12/04/2002 | EP1262482A1 Novel compound having antimalarial activity |
| 12/04/2002 | EP1262477A1 Anti-acid-fast bacterial agents containing pyridonecarboxylic acids as the active ingredient |
| 12/04/2002 | EP1262475A1 Indole derivatives, process for preparation of the same and use thereof |
| 12/04/2002 | EP1262200A2 Inhibition of platelet adherence and aggregation |
| 12/04/2002 | EP1262198A1 Composition with sustained release of levodopa and carbidopa |
| 12/04/2002 | EP1262197A2 Combination treatment for sleep disorders including sleep apnea |
| 12/04/2002 | EP1262196A2 Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence |
| 12/04/2002 | EP1262195A1 Vasoactive agents |
| 12/04/2002 | EP1262186A1 Azalide antibiotic compositions |
| 12/04/2002 | EP1262185A1 Synergistic antibiotic compositions |
| 12/04/2002 | EP1262184A1 Compositions comprising S-tofisopam and use of these compositions for the preparation of a medicament for the treatment or prevention of convulsions or seizures |